Background. Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal malignancies worldwide. The JAK/STAT signaling pathway is involved in pancreatic cancer tumorigenesis. However, the prognostic value of JAK2 expression in resectable PDAC is unclear. Method. In this study, we performed a clinicopathological analysis of 62 resectable PDAC cases with a primary focus on survival. JAK2 expression was examined by immunohistochemistry. The relationship between JAK2 expression and clinicopathological features and prognosis was analyzed. Results. Survival curve analyses revealed that high levels of JAK2 expression predict a poor prognosis in resectable PDAC patients. Multivariate analysis confirmed that JAK2 expression can predict the prognosis of PDAC. Conclusions. Assessment of JAK2 protein expression may be a promising method to predict prognosis in patients with resectable PDAC.

中文翻译：

---

JAK2 蛋白高表达预示可切除胰腺导管腺癌患者预后不良

背景。胰腺导管腺癌（PDAC）是全球最致命的恶性肿瘤之一。JAK/STAT 信号通路参与胰腺癌的肿瘤发生。然而，可切除 PDAC 中 JAK2 表达的预后价值尚不清楚。方法。在这项研究中，我们对 62 例可切除的 PDAC 病例进行了临床病理学分析，主要关注生存率。通过免疫组织化学检查 JAK2 表达。分析JAK2表达与临床病理特征及预后的关系。结果。生存曲线分析显示，高水平的 JAK2 表达预示可切除的 PDAC 患者预后不良。多因素分析证实JAK2的表达可以预测PDAC的预后。结论。JAK2 蛋白表达的评估可能是预测可切除 PDAC 患者预后的一种有前途的方法。